Capstone reaffirms 2026 outlook for $72.1 million revenue, $18.7 million gross profit, $3.8 million adjusted EBITDA
CAPS•Second-half growth outlook
Capstone said current order volumes point to continued strong organic growth in the second half of 2026.
2026 guidance reaffirmed
Capstone Therapeutics reaffirmed full-year 2026 guidance for:
- Revenue: $72.1 million
- Gross profit: $18.7 million
- Stone Business Adjusted EBITDA: about $3.8 million
The company said the outlook follows Q2 organic distribution revenue growth of about 7% year over year, even as the market declined an estimated 8.5%.
